Vitrolife AB (publ) (VTRLY)
Vitrolife AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Gothenburg, VG, SE. The stock last traded at $9.50, up 0.00% on the session, giving a market capitalisation of $1.29B. On trailing twelve-month figures it carries a trailing P/E of -2.45, a net margin of -147.0%. Its beta of 1.71 implies it has historically moved more than the broad market.
Vitrolife AB (publ) is a Swedish medical technology company, established in 1994 and headquartered in Gothenburg. Its core business involves the development, manufacturing, and distribution of specialized products catering to assisted reproductive technologies (ART). The company offers a comprehensive portfolio that includes essential tools for the in vitro fertilization (IVF) process, such as oocyte retrieval needles, solutions for sperm preparation, and advanced IVF culture media and oils. Beyond these, Vitrolife supplies a range of laboratory necessities like micromanipulation pipettes, general labware, and various types of incubators, alongside products for cryopreservation and preimplantation genetic testing. A significant part of its offering comprises cutting-edge time-lapse systems, notably EmbryoScope and Primo Vision, complemented by specific dishes and analytical tools for embryo evaluation. The company also provides Octax laser and imaging systems, in addition to monitoring equipment such as log and guard systems with wireless sensors. Vitrolife operates on a global scale, serving markets across Europe, the Middle East, Africa, Asia, Japan, the Pacific region, and both North and South America. The firm adopted its current name in 1998, having previously been known as Scandinavian IVF Science.
Vitrolife AB (publ) is most often compared with the following Healthcare names: